MBOT vs TRVI vs IDYA vs SSYS

For growth investors, IDEAYA Biosciences, Inc.

(IDYA) is the stronger pick with 30. 2% revenue growth year-over-year, versus -3. 7% for Stratasys Ltd. (SSYS). Analysts rate Microbot Medical Inc. (MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Trevi Therapeutics, Inc.

(TRVI) delivered a total return of +569. 0%, compared to -69. 7% for Microbot Medical Inc. (MBOT). Over 10 years, the gap is even starker: IDYA returned +152. 4% versus MBOT's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Trevi Therapeutics, Inc.

(TRVI) is the lower-risk stock at 1. 06β versus Microbot Medical Inc. 's 1. 85β — meaning MBOT is approximately 75% more volatile than TRVI relative to the S&P 500. On balance sheet safety, Trevi Therapeutics, Inc. (TRVI) carries a lower debt/equity ratio of 0% versus 3% for Microbot Medical Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEAYA Biosciences, Inc.

(IDYA) is pulling ahead at 30. 2% versus -3. 7% for Stratasys Ltd. (SSYS). On earnings-per-share growth, the picture is similar: IDEAYA Biosciences, Inc. grew EPS 61. 9% year-over-year, compared to 24. 7% for Stratasys Ltd.. Over a 3-year CAGR, IDYA leads at 62. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Microbot Medical Inc.

(MBOT) is the more profitable company, earning 0. 0% net margin versus -52. 0% for IDEAYA Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBOT leads at 0. 0% versus -72. 8% for IDYA. At the gross margin level — before operating expenses — IDYA leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MBOT: 158.

2% to $5. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Trevi Therapeutics, Inc.

(TRVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 06)). Microbot Medical Inc. (MBOT) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TRVI: +78. 1%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MBOT (Healthcare) and TRVI (Healthcare) and IDYA (Healthcare) and SSYS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MBOT is a small-cap quality compounder stock; TRVI is a small-cap quality compounder stock; IDYA is a small-cap high-growth stock; SSYS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.